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ABSTRACT
Objective To evaluate the incidence of serious maternal
complications after the use of various tocolytic drugs for
the treatment of preterm labour in routine clinical
situations.
Design Prospective cohort study.
Setting 28 hospitals in the Netherlands and Belgium.
Participants 1920 consecutive women treated with
tocolytics for threatened preterm labour.
Main outcome measuresMaternal adverse events (those
suspected of being causally related to treatment were
considered adverse drug reactions) leading to cessation
of treatment.
Results An independent panel evaluated the recorded
adverse events, without knowledge of the type of tocolytic
used. Of the 1920 women treated with tocolytics, 1327
received a single course of treatment (69.1%), 282
sequential courses (14.7%), and 311 combined courses
(16.2%). Adverse drug reactions were categorised as
serious or mild in 14 cases each. The overall incidence of
serious adverse drug reaction was 0.7%. Compared with
atosiban, the relative risk of an adverse drug reaction for
single treatment with a β adrenoceptor agonist was 22.0
(95% confidence interval 3.6 to 138.0) and for single
treatment with a calcium antagonist was 12 (1.9 to 69).
Multiple drug tocolysis led to five serious adverse drug
reactions (1.6%). Multiple gestation, preterm rupture of
membranes, and comorbidity were not independent risk
factors for adverse drug reactions.
Conclusions The use of β adrenoceptor agonists or
multiple tocolytics for preventing preterm birth is
associated with a high incidence of serious adverse drug
reactions. Indometacin and atosiban were the only drugs
not associated with serious adverse drug reactions. A
direct comparison of the effectiveness of nifedipine and
atosiban in postponing preterm delivery is needed.
INTRODUCTION
Preterm labour is the most reported cause of perinatal
morbidity and mortality in the Western world.1 2
Tocolytic drugs have not been shown to improve
fetal outcome, but are used to postpone delivery for 48
hours to allow formaximal effect of parenteral steroids
administered to themother and to enable themother to
be transferred to a centrewith a neonatal intensive care
unit.3 In the absence of any clear evidence that one
tocolytic is more efficacious than another, relative
safety is the main reason for choosing one over the
other. The drugs registered for tocolysis include the β
adrenoceptor agonist ritodrine hydrochloride (United
States and Europe) and the oxytocin receptor antago-
nist atosiban (Europe). Cyclo-oxygenase inhibitors
and calcium channel blockers are also used for
inhibiting preterm labour,4 5 although they are not
currently registered for this indication.
β adrenoceptor agonists cause adverse effects in
women more often than any other tocolytic drug.67 In
a clinical trial setting the oxytocin receptor antagonist
atosibanwas associatedwith fewer adverse effects than β
adrenoceptor agonists (relative risk 0.04, 95% confi-
dence interval 0.02 to 0.11) with comparable effective-
ness (proportion of women with birth delayed for 48
hours; relative risk 1.1, 0.9 to 1.2).7-9 When compared
with placebo, however, atosibanwas not associatedwith
a reduction in the incidence of neonatal respiratory
distress syndrome, a serious complication of
prematurity.9 Small studies using cyclo-oxygenase
inhibitors have suggested that indometacin reduces the
proportionofwomendeliveringpretermcomparedwith
placebo (relative risk 0.2, 0.1 to 0.6),5 but its use has been
limited because of concerns about adverse effects of
cyclo-oxygenase inhibitors on fetal kidneys and ductus
arteriosus and the increased risk of intraventricular
haemorrhage and necrotising enterocolitis.1011 Calcium
channel blockers seem to be more effective in postpon-
ing preterm delivery (relative risk 0.8, 0.6 to 0.9) and
reducing neonatal respiratory distress (0.6, 0.4 to 0.9)
than do β adrenoceptor agonists.412 However, placebo
controlled trials assessing calcium channel blockers are
not available and recent reports have raised concerns
about women’s safety with use of these tocolytic
drugs.1314 The choice of first line tocolytic drugs for the
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treatment of preterm labour is therefore controversial
because of inconclusive information on the relative
safety of the various agents.1516 For example, most
randomised trials on the efficiency and side effects of
tocolytic drugs have generally been restricted to well
defined (low risk) populations, excluding women with
multiple gestation, preterm rupture of membranes,
vaginal bleeding, diabetes, or a history of cardiovascular
diseases. No prospective study has compared the
adverse reactions of women to different tocolytic drugs
in a routine clinical setting.We carried out a prospective
cohort study in theNetherlands andBelgium to evaluate
the incidence of seriousmaternal complications with the
use of the various tocolytic drugs to treat preterm labour
in routine clinical situations.
METHODS
We carried out an open label, prospective, cohort
study. The cohort comprised consecutive women who
were treated with tocolytic drugs according to local
protocol for preterm labour in 28 hospitals in the
Netherlands and Belgium during January 2006 to July
2007. We excluded women who were treated with
tocolytic drugs for other reasons, such as external
cephalicversion forbreechpresentationor intrauterine
resuscitation in case of suspected fetal distress during
term labour. Potential participants were identified by
the attending doctor or a study nurse and registered
through a study website, which was accessible to
participating clinics using centre specific access codes.
We recorded the personal and obstetrical character-
istics for each woman, including the date of birth,
gestational age, parity, cervical dilation, blood loss,
intact versus ruptured membranes, number of fetuses,
and the presence of comorbidities such as cardio-
pulmonary disease, pre-eclampsia, hypertension, dia-
betes, placenta abnormalities, or polyhydramnios.We
also recorded the type of tocolytic treatment and any
maternal adverse event that required cessation of
treatment. The attending obstetrician decided when
to stop treatment in case of an adverse event. We
carried out quality control of patient registration by
checking the dispensing lists for tocolytics from the
pharmaceutical department at each participating hos-
pital. In all cases of possible adverse events the
principal investigator completed a standard case
report. If necessary, we retrieved additional data from
the patients’ files.
Data assessment
At the end of the registration period all adverse events
were evaluated and classified by a panel of five
members; three obstetricians (J-JHME, HW, MH)
and two pharmacologists (LH, FFAMS). Four mem-
bers of the panel worked in university hospitals and the
fifth was an administrator at the Dutch Pharmaco-
vigilance Centre.
Thepanelwas initially asked to establishwhether the
registered adverse events satisfied the criteria of
occurring during tocolysis and requiring discontinua-
tion of tocolytic treatment in the opinion of the
attending obstetrician, and then to classify the adverse
events in terms of severity (serious or mild). The
members individually reviewed all cases of adverse
events, blind to the type of tocolytic used. For serious
adverse events, we used the definition of the Council
for International Organizations of Medical Sciences as
a guideline.17 According to the council a serious
adverse event is one that results in death, is life
threatening, requires admission to hospital or prolon-
gation of existing hospital stay, results in persistent or
important disability or incapacity, or is a congenital
anomaly or birth defect. On the basis of this definition,
a serious adverse event in the context of tocolytic drugs
was any of the following: severe hypotension (systolic
blood pressure <100 mm Hg and >20% drop
compared with baseline values), severe dyspnoea,
lung oedema, myocardial infarction, anaphylactic
shock, admittance to intensive care, or maternal
death. A mild adverse event was defined as an adverse
event that led to cessation of tocolytic therapy (for
example, tachycardia, nausea, dizziness, headache) but
did not meet the criteria for a serious adverse event.
Each panelmember subsequently received the list of
adverse events, previously categorised as mild or
serious, and the tocolytic used. They were asked to
assesswhether the adverse eventswere causally related
to each tocolytic, using the causality categories of the
World Health Organization: certain, probable, possi-
ble, unlikely, conditional, andnon-assessable.18 Impor-
tant criteria for the assessment of causality were the
association in time between administration of the
tocolytic and event, pharmacological features,medical
plausibility, and exclusion of other causes. In cases of
rechallenge with the tocolytic and recurrence of the
adverse event, the causal relation to treatment was
classified as certain. In case of a reasonable relation
with time, not likely to be attributable to other drugs or
disease, and a reasonable clinical response to with-
drawal, the causal relation to treatmentwas classified as
probable. If the adverse event could also be explained
by concomitant diseases or use of other drugs, the
causal relation to treatment was classified as possible.
For adverse events with an improbable time relation or
a plausible explanation provided by concomitant
diseases or the use of other drugs the causal relation
to treatment was classified as unlikely. The cases with
discrepant assessments were discussed during a plen-
ary meeting and a consensus was reached in all cases.
We defined all adverse events that were considered as
possibly, probably, or certainly related to tocolytic
treatment as adverse drug reactions.
Analysis
Weclassified theadministrationof tocolytics according
to three courses of treatment: single (one tocolytic),
sequential (multiple tocolytics given separately in
sequence), or combined (multiple tocolytics given
simultaneously). The primary outcome of the study
was the incidence of serious adverse drug reactions to
tocolytics. In each of the three treatment categories we
calculated the incidence of a tocolytic related adverse
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drug reaction. For single course treatments, we carried
out a separate analysis for each type of tocolytic. We
then calculated the relative risk, the associated 95%
confidence interval, and the number needed to harm,
using the single course tocolytic with the lowest
incidence as a reference category. Using logistic
regression we carried out a subgroup analysis of
possible contributing factors to the incidence of
tocolytic related adverse drug reactions, such as
multiple gestation, medical history, or any obstetric
comorbidity.
RESULTS
From January 2006 to July 2007, 1920 women were
treated with tocolytic drugs in 28 hospitals in the
Netherlands andBelgium. Themeanmaternal agewas
29.8 years (interquartile range 26.4-33.3 years), and the
mean gestational age was 29weeks (interquartile range
27-31 weeks). Table 1 summarises the obstetrical
characteristics of these women and the types of
tocolytic treatment they received. The tocolytic agents
used, either singly, combined, or sequentially, were the
calcium channel blocker nifedipine (n=1022, 34.3%),
theoxytocinantagonist atosiban (n=1248, 41.9%), theβ
adrenoceptor agonists ritodrine and fenoterol (n=411,
13.8%), the cyclo-oxygenase inhibitor indometacin
(n=261, 8%), magnesium sulphate (n=18, 0.6%), and
transdermal nitroglycerin, a nitric oxide donor (n=4).
Adverse events were recorded in 38 women in 17
hospitals. The panel rejected seven cases: in four cases
the tocolytic had not stopped preterm labour and was
therefore discontinued, in one case the dose of the
tocolyticwas reducedbut treatmentwasnot stopped, in
one case treatment was stopped because of fetal
tachycardia and not to a maternal event, and in one
case treatment was stopped because of the inappropri-
ate use of a βmimetic in a womanwith diabetes. Of the
remaining 31 cases, 16 were categorised as serious
adverse events and 15 asmild (tables 2 and 3). A causal
relation to treatment was considered as unlikely in two
cases of serious adverse events (table 2) and in one case
of mild adverse events (table 3). These cases were
therefore not included in further analyses, leaving 14
serious adverse drug reactions and 14 mild adverse
drug reactions. Four women needed intensive care, all
aftermultiple treatment with tocolytics. All thewomen
who experienced adverse events recovered without
persistent or major disability or incapacity. No fetal
deaths were reported during treatment and none of the
mild or serious adverse drug reactions was followed by
fetal or neonatal death.
Among 575 women treated with a single course of
atosiban, none had a serious adverse drug reaction and
one had a mild adverse drug reaction (0.2%; table 4).
Among 542 women treated with nifedipine, five had a
serious adverse drug reaction (0.9%) and six had amild
adverse drug reaction (1.1%). Among 175 women
treated with β adrenoceptor agonists, three had a
serious adverse drug reaction (1.7%) and four had a
mildadversedrug reaction (2.3%).Thenumberneeded
to treat to prevent a serious adverse drug reaction with
atosiban compared with β adrenoceptor agonists was
59 (lower limit of 95% confidence interval was 35) and
compared with nifedipine was 108 (lower limit of 95%
confidence interval was 56). In comparison with
atosiban, the relative risk of an adverse drug reaction
(mild and serious combined) with β adrenoceptor
agonistswas22.0 (95%confidence interval3.6 to138.0)
and with nifedipine was 12 (1.9 to 69.0).
Ten different combinations of atosiban, β adreno-
ceptor agonists, nifedipine, and cyclo-oxygenase inhi-
bitors were recorded in 311 instances. In patients who
received these combinations, five serious (1.6%) and
onemild (0.3%) adverse drug reactionswere observed.
No serious adverse drug reaction was reported in
Table 1 | Obstetrical characteristics of women who received tocolytic treatment. Values are numbers (percentages) of women
Variables
Single course treatment
Sequential
courses (n=282)
Combined courses
(n=311)
Atosiban
(n=575)
Nifedipine
(n=542)
βmimetics
(n=175)
Cyclo-oxygenase inhibitors
(n=35)
Singleton pregnancy 441 (77) 441 (82) 159 (81) 28 (80) 213 (76) 224 (72)
Parity 0 294 (51) 284 (52) 92 (53) 10 (29) 151 (54) 182 (59)
Preterm rupture of membranes 162 (28) 162 (30) 35 (20) 3 (9) 59 (21) 87 (28)
Cardiac history 15 (2.6) 10 (1.8) 3 (1.7) 0 3 (1) 4 (1.3)
Diabetes types 1 and 2 and gestational 5 (0.9) 4 (0.7) 0 0 3 (1) 2 (0.6)
Table 2 | Serious maternal adverse events associated with tocolytic treatment
Serious adverse event Tocolytic
No of
fetuses
Intensive
care Causality
Dyspnoea Ritodrine 1 No Probable
Dyspnoea Fenoterol 1 No Probable
Dyspnoea Atosiban, nifedipine, and ritodrine* 1 No Probable
Dyspnoea Fenoterol 1 No Probable
Dyspnoea Nifedipine 2 No Possible
Dyspnoea Atosiban and fenoterol* 1 Yes Possible
Hypotension Nifedipine 1 No Probable
Hypotension Nifedipine 1 No Certain
Hypotension Nifedipine 2 No Certain
Hypotension Nifedipine 1 No Certain
Cardiac failure Atosiban then fenoterol† 1 Yes Possible
Hypoxia Nifedipine and ritodrine* 2 No Probable
Lung oedema Atosiban, nifedipine, and fenoterol* 2 Yes Possible
Lung oedema Atosiban and nifedipine* 1 Yes Probable
Dyspnoea Fenoterol 1 No Unlikely
Deep vein thrombosis Ritodrine then nifedipine† 2 No Unlikely
*Combined courses: event occurred after simultaneous administration of all indicated tocolytics.
†Sequential courses: event occurred after administration of second tocolytic.
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combinations using cyclo-oxygenase inhibitors
(n=143). In 282 women who received sequential
courses one serious and two mild (0.7%) adverse drug
reactions were observed, all during administration of
the second drug; once with a βmimetic drug and twice
with nifedipine.
The use of tocolytics was recorded in 414 women
with a multiple pregnancy. Four of these women had a
serious tocolytic related adverse drug reaction com-
paredwithwomenwith a singleton pregnancy (relative
risk 1.5, 95% confidence interval 0.39 to 5.0). Two of
the women (2.0%) were treated with a single course of
nifedipine (n=101) and two (2.4%) were treated with
combined courses (n=84). Logistic regression showed
that preterm rupture of membranes, blood loss, and
other obstetric comorbidities were not independently
related to an adverse event.
DISCUSSION
The use of β adrenoceptor agonists or multiple
tocolytics to prevent preterm labour is associated
with a high incidence of serious adverse drug reactions.
Indometacin and atosiban were the only tocolytic
drugs not associated with serious adverse reactions.
Randomised studies on the efficiency of tocolytics
and adverse events associated with these drugs have
generally been restricted to well defined (low risk)
populations, excluding womenwithmultiple pregnan-
cies, preterm rupture of membranes, vaginal bleeding,
diabetes, or a history of cardiovascular diseases;
however, many of the case reports on adverse drug
reactions to tocolytics have been associated with these
conditions.13 19-22Weassessed theoccurrence of serious
maternal adverse drug reactions related to the use of
different tocolytics in a routine clinical setting. Our
results therefore apply to situations normally encoun-
tered in clinical practice, where both low risk and high
risk cases are observed. Intense monitoring in a trial
setting is, however, likely to reveal all mild and serious
maternal side effects, whereas under-reporting of
adverse experiences cannot be excluded inprospective
multicentre cohort studies where the intensity of
monitoring—especially of blood pressure—may vary
between hospitals.
In our study the overall incidenceof serious tocolytic
related adverse drug reactions was low (0.7%). The
incidence of serious adverse drug reactions in women
receiving combined courses of tocolytics (16.2% of all
patients) was, however, high (1.6-2.5%). As there is no
evidence that treatment with combined tocolytics is
superior to single or sequential treatment, we believe
that combined treatment should be discouraged. In
women treated with a single tocolytic, the incidence of
serious adverse drug reactions was 1.7% for βmimetic
agents and 0.9% for nifedipine. No serious adverse
drug reaction was observed after treatment with a
single course of atosiban. Most of the adverse drug
reactions reported in women treated with nifedipine
were related to theeffectsof thedrugonbloodpressure.
In six of the seven cases, hypotensiondevelopedwithin
two to four hours after the start of tocolysis. The
treatment schedule was usually the following: two to
four doses of 10 mg sublingual nifedipine every
15 minutes, followed by 20 mg slow release nifedipine
every four hours. With such a regimen, plasma levels
are likely to peak between 60 and 80 minutes after
administration and cause a concomitant fall in blood
pressure.23 In our series, the relevance of this finding
seems low, given the absence of obvious fetal
compromise in the 542 women treated with nifedipine
only.Fetal compromiseafter ahypotensiveepisodehas
been found in studies of animals and in several cases in
humans, including one fetal death.24-26 In the case of the
death of the fetus, blood pressure dropped after the
Table 3 | Mild maternal adverse events associated with tocolytic treatment
Mild adverse events Tocolytic No of fetuses Causality
Hypotension Nifedipine 2 Possible
Hypotension Nifedipine 1 Probable
Hypotension Nifedipine 1 Probable
Tachycardia Nifedipine 1 Possible
Tachycardia Atosiban then nifedipine* 1 Possible
Tachycardia Ritodrine 1 Probable
Tachycardia Fenoterol 1 Probable
Tachycardia Nifedipine 1 Probable
Tachycardia Fenoterol 1 Certain
Nausea Atosiban 1 Possible
Headache Atosiban then nifedipine* 1 Possible
Headache Fenoterol 1 Probable
Headache Atosiban, nifedipine, ritodrine, and minitran† 1 Probable
Headache Nifedipine 1 Probable
Syncope Nifedipine 1 Unlikely
*Sequential courses: event occurred after administration of second tocolytic.
†Combined courses: event occurred after simultaneous administration of all indicated tocolytics.
Table 4 | Adverse drug reactions associated with single tocolytic treatment. Values are numbers (percentages) of women unless
stated otherwise
Tocolytic No of patients
Severity of adverse drug reaction
Total Relative risk* (95% CI)Serious Mild
βmimetics 175 3 (1.7) 4 (2.3) 7 (4.0) 3.8 (1.6 to 9.2)
Nifedipine 542 5 (0.9) 6 (1.1) 11 (2.0) 2.0 (0.8 to 4.8)
Atosiban 575 0 1 (0.2) 1 (0.2) 0.07 (0.01 to 0.4)
Cyclo-oxygenase inhibitors 35 0 0 0 NA
NA=Not applicable.
*For total adverse drug reactions.
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mother had chewed two 10 mg nifedipine tablets at an
interval of minutes.24
Inmostof the recent case reports that raisedconcerns
about the safety of calcium antagonists in women,
complicating factors such as multiple pregnancy,
cardiovascular disease, diabetes, or infections were
present.13 21 27 28 We did not find any significant
association between adverse drug reactions to nifedi-
pine and these factors. We found four serious adverse
drug reactions in women with multiple pregnancy—
two women receiving nifedipine (2%) and two receiv-
ing combined treatment (2.4%). These incidenceswere
not significant. Whether this was due to lack of
statistical power is uncertain.
β adrenoceptor agonists do not seem to be more
effective than atosiban, nifedipine, or cyclo-oxygenase
inhibitors in preventing preterm birth,4 5 7 8 12 and our
results confirm the high incidence of adverse drug
reactions with use of these agents for tocolysis.6 7 This
justifies the use of alternative tocolytic drugs. In our
study only a few women were treated with cyclo-
oxygenase inhibitors, most likely because in Belgium
and the Netherlands these drugs are restricted to
women in early gestation. Moreover, concerns about
fetal side effects limit the use of cyclo-oxygenase
inhibitors for tocolysis.10 11 We found no adverse drug
reactions, either with single treatment or with treat-
ment using cyclo-oxygenase inhibitors combined with
other tocolytics. A recent meta-analysis of cyclo-
oxygenase inhibitors showed that indometacin
reduced the proportion of women delivering preterm
(<37weeks’gestation; relative risk0.5, 95%confidence
interval 0.3 to 0.9), with only one case of antenatal
closure of the ductus arteriosus among 403 women
treated short term (up to 48 hours).5 Nonetheless, on
the basis of the volume of evidence the authors
concluded that firm conclusions on the efficiency and
safety for neonates when using cyclo-oxygenase
inhibitors to prevent preterm delivery could not be
drawn.
Large randomised controlled trials comparing ato-
siban with nifedipine are lacking. An indirect compar-
ison of atosiban with nifedipine, using β adrenoceptor
agonists as a common comparator, has been
published.29 The analysis showed no significant
differences in effectiveness in delaying delivery, but a
significant reduction in neonatal respiratory distress
syndrome with nifedipine. Whether this reduction is
attributable to a difference in effectiveness of the drug
or to differences between the analysed trials in terms of
lack of blinding or concealment or of corticosteroid
administration remains uncertain.
An ideal tocolytic should postpone delivery at low
costs without maternal and fetal side effects. None of
the tocolytics described in this study fulfils these
criteria.We found that combined treatment or a single
treatment using β adrenoceptor agonists led to a higher
incidence of serious adverse drug reactions, and such
treatments should be discouraged. The overall inci-
dence of serious adverse drug reactions with a single
course of nifedipine in a singleton pregnancy seems to
be low, but not absent. Atosiban has the best maternal
and fetal safety profile but at considerable cost.Adirect
comparison of effectiveness between oxytocin antago-
nists and calcium channel blockers is lacking. More-
over, larger studies with different dose regimens for
nifedipine are necessary to compare efficiency and
maternal side effects.
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